Investigational drug · Phase 2
LP-98
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV.
Phase 2Last checked: Nov 19, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "LP-98"
First trial start
2026
Jan 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LP-98", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "LP-98" as an intervention, largest first.
- Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected PatientsCompleted
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT06560489 · 40 participants · Start Sep 2, 2024 · Primary completion Jan 10, 2025
Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98. · For: Hiv
Sites: Zhengzhou, China
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT05933824 · 36 participants · Start Jul 13, 2023 · Primary completion Apr 12, 2024
Drug: LP-98 injection · For: HIV (Human Immunodeficiency Virus)
Sites: Zhengzhou, China
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT07433387 · 30 participants (planned) · Start Jan 29, 2026 · Primary completion Jul 10, 2026
Drug: LP-98 20 mg; LP-98 40 mg and 1 more · For: HIV
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- A four-amino-acid deletion in gp41 enhances HIV-1 CRF01_AE Cluster 4 pathogenicity and fusion inhibitor resistance.
Zhang D, Han J, Liu C, et al. · J Virol 2026
- Novel HIV fusion-inhibitory lipopeptides exhibit dramatically improved activity against resistant mutants.
Zhu Y, Chen T, Liu N, et al. · Mol Ther 2026
- Peptide inhibitors recognize prefusion viral fusion proteins with heterogeneous stoichiometry and rapid kinetics.
Katte RH, Liu J, He Y, et al. · bioRxiv 2026
- An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques.
Xue J, Zhu Y, Yang C, et al. · Cell Rep 2025
- Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms.
Liu N, Zhu Y, Chong H, et al. · Antiviral Res 2025
- Prolonged release and antiviral efficacy of HIV fusion inhibitor LP-98-loaded microspheres in rhesus macaques.
Cong Z, Wei Y, Chong H, et al. · J Control Release 2024
Also in development for HIV
- AlimatravirMK-8527Phase 34 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV
- Dispensing CodivirPhase 21 trial
Code Pharma · HIV, HIV Infection
- LipovirtidePhase 21 trial
Shanxi Kangbao Biological Product Co., Ltd. · HIV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.